By Delphine Guyon-Gellin (Osivax)2024-03-26T08:48:45
Join us for our Women in STEM series with Delphine Guyon-Gellin, Chief Business Development Officer at Osivax. She joined the company in 2018 with 15 years of experience in vaccine business and strategy. Prior to her work at Osivax, Delphine worked as a strategic consultant for leading pharmaceutical companies, helping ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-08-28T10:00:24Z
2023-07-04T10:05:58
Sponsored by Revvity
2024-01-26T13:22:42
Sponsored by bit.bio
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2024-05-10T11:23:31
Sponsored by BellBrook Labs
2023-01-10T09:50:16
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2024-02-02T15:48:26
Sponsored by Bio-Techne
Site powered by Webvision Cloud